Search Bar & Filters
Found 25 Actively Recruiting clinical trials
Actively Recruiting
Researchers are conducting the BALANCE platform trial to study different treatment strategies for Gram-negative bloodstream infections GN BSIs. This adaptive trial addresses important questions about managing these infections, which have high risks and are complicated by increasing antibiotic resistance. The trial builds on previous research and aims to improve treatment approaches and patient outcomes while addressing antimicrobial resistance challenges. Participants in the trial receive various treatments depending on the domain they are assigned to. These include strategies such as antibiotic de-escalation or continuation, use of oral beta-lactams versus non-beta-lactams, decisions about replacing or retaining central vascular catheters, comparison of cephalosporins versus carbapenems for certain bacteria, and whether to perform routine follow-up blood cultures. The trial is open-label and embedded in routine hospital care, with an adaptive design that allows adding or removing treatment domains over time. During the study, participants undergo regular evaluations including monitoring for death, reinfection, readmission, and development of antimicrobial resistance over 90 days. The main measurement used is the Desirability of Outcome Ranking DOOR scale. Interim analyses occur frequently to assess results and determine continuation. Participation includes hospital admission, treatment under routine care with study interventions, and follow-up for outcome assessments. The study is planned to continue until April 2028 and enrolls patients from newborns to elderly adults.
Actively Recruiting
Researchers are evaluating the use of intravenous hyperoncotic albumin compared to normal saline boluses in critically ill patients suffering from Acute Kidney Injury requiring renal replacement therapy AKI-RRT. This trial aims to determine whether albumin administration during renal replacement therapy sessions increases organ support-free days and renal replacement therapy-free days within 28 days after randomization. The study addresses the challenge that renal replacement therapy, while life-saving, may cause complications like hypotension and organ ischemia in these patients. Participants will be randomly assigned to receive either 20-25% albumin fluid or normal saline boluses during their renal replacement therapy sessions in the intensive care unit. Each treatment involves two 100 mL boluses one at the start and one halfway through each session. The renal replacement therapies include continuous renal replacement therapy CRRT, prolonged intermittent renal replacement therapy PIRRT, or intermittent hemodialysis IHD. Treatments will continue for up to 14 days in the ICU, with dosing schedules tailored to the type of renal replacement therapy. During the study, participants will be closely monitored for organ support-free days, renal replacement therapy-free days, and other health outcomes through 28 days, with extended follow-up for mortality and kidney function up to 365 days. Researchers will collect data on fluid balance, hypotension episodes during therapy, organ function scores, healthcare costs, and quality of life measures. The trial involves multiple intensive care units and includes comprehensive assessments to evaluate the impact and safety of albumin use in this critical condition.
Actively Recruiting
This research aims to compare the effects of oral anticoagulation versus no anticoagulation in patients aged 55 and older who have had recent episodes of transient atrial fibrillation triggered by stress and have additional factors that increase their risk of stroke. The study is a multinational, investigator-initiated, prospective, randomized, open-label trial evaluating the impact of non-vitamin K oral anticoagulants NOACs on preventing stroke and other serious cardiovascular events. Participants will be randomly assigned to either receive one of several NOACs, such as edoxaban, apixaban, dabigatran, or rivaroxaban, prescribed by their physician for the duration of the follow-up, or to a control group that will not receive anticoagulants unless medically indicated during the study. The choice of specific NOAC and dose adjustments are determined by the prescribing doctor. The study excludes patients with certain conditions like chronic atrial fibrillation, severe kidney or liver disease, recent cardiac surgery, or bleeding risks. During the study, participants will be monitored for up to 24 months to assess the occurrence of non-hemorrhagic stroke, systemic embolism, vascular mortality, myocardial infarction, peripheral arterial thrombosis, amputation, and venous thromboembolism. Regular follow-up will include evaluation of these outcomes to measure the effectiveness and safety of anticoagulation compared to no anticoagulation. Participants will provide informed consent and remain under medical supervision throughout the trial.
Actively Recruiting
Researchers are evaluating the effects of therapeutic-dose heparin compared to usual care pharmacological thromboprophylaxis in patients hospitalized with community-acquired pneumonia CAP. The study focuses on the high incidence of hospitalizations due to CAP, which often leads to serious complications including thrombotic events that affect respiratory, cardiac, and other organs. This trial aims to explore whether therapeutic-dose heparin can improve outcomes by targeting inflammatory and thrombotic pathways, a strategy shown to help in COVID-19 but not yet studied in non-COVID-19 CAP. Participants are randomly assigned to one of two groups. One group receives therapeutic-dose low molecular-weight heparin LMWH or unfractionated heparin UFH daily for up to 14 days or until hospital discharge, whichever comes first. The other group receives the usual care thromboprophylaxis dose according to local practice, which is lower than the therapeutic dose. Treatments start as soon as possible after randomization. LMWH is preferred unless contraindicated, with dosing based on patient weight, while UFH may be used in cases of renal impairment. During the study, participants will be monitored for outcomes including survival at 30 days, bleeding events, thrombotic events, mechanical ventilation use, mortality at various timepoints, hospital-free days, and health-related quality of life. The study collects data up to 180 days after treatment. Safety monitoring includes tracking adverse events like bleeding and heparin-induced thrombocytopenia. Participation involves hospital stays expected to last at least 72 hours from randomization, with assessments throughout the treatment period and follow-up extending to 180 days.
Actively Recruiting
Researchers are evaluating the effectiveness of two antiviral drugs, Paxlovid and Veklury, in preventing long-term cardiovascular problems following COVID-19 among hospitalized adults. This study, called the DEFEND trial, will be the first of its kind to focus on cardiovascular post-acute sequelae of SARS-CoV-2 in this patient group. It is a pilot, randomized, placebo-controlled trial designed to also help plan a larger future study by testing recruitment feasibility and accuracy of hospital outcome data. Participants will be randomly assigned to receive either Paxlovid orally twice daily for 5 days or Veklury intravenously once daily for 5 days, alongside standard care, or a matching placebo on the same schedule. The trial will enroll adults aged 18 or older who have tested positive for SARS-CoV-2 within 5 days of hospital admission and are not requiring supplemental oxygen. The study will recruit about 118 participants across four hospitals in Ontario, followed by a 12-month observation period after treatment. During the study, researchers will monitor participants from the time of screening through enrollment and track major cardiovascular events such as stroke, heart failure, venous thromboembolism, diabetes, or death within one year. They will also validate hospital data accuracy, assess reinfection, ICU admission, and drug safety within 90 days of the initial COVID-19 test. The trial includes thorough follow-up and safety monitoring over the full year to understand the long-term cardiovascular outcomes related to COVID-19 and the potential preventive effects of the antiviral treatments.
Actively Recruiting
Researchers are evaluating routine supportive care interventions used in intensive care units ICUs worldwide through the Canadian Critical Care Comparative Effectiveness Platform CEPEC, an international multi-center randomized adaptive platform clinical trial. The study focuses on several care domains including vasopressors, nutrition, platelet transfusions, sedation and analgesia, airway management, and end-of-life care practices, aiming to improve the understanding of these resource-intensive treatments. The trial includes multiple domains the Vasopressor Domain tests different mean arterial pressure MAP targets for patients in cardiovascular shock using vasoactive medications the Platelet Domain assesses platelet transfusion thresholds for thrombocytopenic ICU patients undergoing low to moderate bleeding risk procedures and the Nutrition Domain compares bolus feeding three times a day versus continuous feeding over 24 hours for critically ill patients requiring enteral nutrition. Participants are randomized within these domains to various treatment groups based on specific criteria. Participants will be closely monitored during their ICU stay with assessments including mortality rates, organ dysfunction, bleeding outcomes, nutritional intake, and quality of life up to 90 days or hospital discharge. Data on recruitment rates and treatment effects are collected to evaluate the interventions. The study is led by Universit de Sherbrooke and follows participants through hospital discharge and beyond, aiming to generate evidence to guide best practices in critical care.
Actively Recruiting
Researchers are evaluating how to best recommend chemotherapy for patients with colon cancer based on the presence or absence of circulating tumor DNA ctDNA after surgery. This Phase IIIII trial aims to determine if ctDNA can be used to better identify patients who need adjuvant chemotherapy and to assess optimal chemotherapy regimens for those with detectable ctDNA, as current biomarkers have not been prospectively validated. Participants are assigned to different groups based on their ctDNA status after surgery. Those without detectable ctDNA may undergo serial ctDNA monitoring without treatment or receive shorter chemotherapy regimens. Patients with detectable ctDNA receive more intensive chemotherapy options, including combinations of oxaliplatin, leucovorin, 5-fluorouracil, irinotecan, or capecitabine, administered intravenously or orally over cycles lasting several weeks. The study includes randomization and uses the Signatera test for central ctDNA detection. During the study, participants will undergo regular blood tests for ctDNA status, imaging scans, and clinical assessments. Researchers will track ctDNA positivity over up to 3 years and disease-free survival over up to 5 years. Other measures include overall survival, recurrence rates, and chemotherapy compliance. The total study duration may extend several years with ongoing monitoring to evaluate safety and treatment outcomes.
Actively Recruiting
This research focuses on patients undergoing noncardiac surgery to detect postoperative atrial fibrillation POAF, a condition linked to long-term health issues but often missed in routine care. The study aims to determine how often clinically important POAF occurs by using continuous heart monitoring after surgery. It is a multicenter prospective cohort study sponsored by the Population Health Research Institute. Participants will wear a portable cardiac monitoring device to continuously record their heart rhythm for up to 14 days, starting within 72 hours after their surgery. The monitoring period can last up to 14 days, and the study observes the incidence of POAF and related heart rhythm problems within 35 days of surgery. This approach seeks to improve detection compared to usual clinical monitoring. During the study, researchers will collect continuous ECG data, and participants will be followed to track heart rhythm events and any complications. The main measurement is the occurrence of clinically important POAF within 35 days after surgery. Secondary outcomes include other heart rhythm disturbances and death within the same period. The total participation time includes continuous monitoring and follow-up assessments within 35 days after surgery.
Actively Recruiting
Researchers are investigating whether adding the drug Docetaxel to the usual hormone treatments, Androgen Deprivation Therapy ADT and Androgen-Receptor Pathway Inhibitor ARPI, can better control metastatic castration sensitive prostate cancer in men who have not responded optimally to initial hormone therapy. This phase III, international, open-label, randomized trial seeks to compare the effectiveness of this combined approach against the standard hormone therapy alone. Participants will be randomly assigned to receive either the standard hormone therapy with ADT plus ARPI or the same hormone therapy combined with Docetaxel chemotherapy. The trial focuses on men with metastatic prostate cancer who continue to have elevated PSA levels after 6 to 12 months of hormone-targeting treatment. Treatments are administered according to physician choice and assignment, and the study evaluates outcomes over a long period. During the trial, participants will be closely monitored with assessments including PSA levels and clinical progression over 39 months. Researchers will measure overall survival as the primary outcome, along with secondary outcomes such as PSA progression, PSA response, PSA kinetics, and progression-free survival. Participants must be accessible for treatment and follow-up to allow for complete documentation of treatment effects and adverse events throughout the study duration.
Actively Recruiting
Healthy Volunteer
Researchers are investigating whether increased consumption of Greek yogurt combined with regular high-impact exercise can improve bone health and reduce inflammation in young competitive athletes aged 15 to 22. The study focuses on male and female varsity and club athletes to see if Greek yogurt offers benefits similar to those from whey protein supplements, which are commonly used by athletes. This research aims to better understand how diet affects bone metabolism during growth and development in young athletes. The study is designed as a randomized controlled trial lasting 24 weeks, beginning with an 8-week control period where participants follow their usual diet and training. Afterward, for 16 weeks, athletes will be randomly assigned to consume either two daily servings of Greek yogurt or whey protein supplements while maintaining their habitual diets. The Greek yogurt servings are 175 g each, and the whey protein servings are 23 of a scoop dissolved in water, with flexibility in timing to fit training schedules. Participants will undergo assessments including blood tests at weeks 0, 8, 16, and 24 to measure markers of bone remodeling, inflammation, sex hormones, and growth factors. Bone strength will be evaluated using ultrasound at the same timepoints, and body composition will be measured by bioelectrical impedance analysis. Dietary intake, nutrition knowledge, and physical activity will be regularly tracked using food diaries, questionnaires, and training logs. The study aims to analyze changes in these measures to understand the effects of Greek yogurt versus whey protein on bone health and inflammation in young athletes.
1-10 of 25
1